ContraVir Pharmaceuticals Selected to Present Two Posters on CRV431 at the Upcoming AASLD Meeting® 2017
August 03 2017 - 6:00AM
ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical
company focused on the development and commercialization of
targeted antiviral therapies, announced today that two abstracts
have been selected by the Scientific Program Committee of the
American Association for the Study of Liver Diseases (AASLD) for
poster presentations on October 21, 2017.
Abstract #1: "Independent and Combinational
Anti-HBV Effects of CRV431 and TXL in the HBV Transgenic Mouse
Model"
- Publication Number: 907
- Date and Time: October 21, 2017 from 2:00
PM to 7:30 PM
- Session: Hepatitis B: New and Approved
Treatment
- Location: Washington Convention Center, Hall
D
Abstract #2: "CRV431 Blocks NTCP-Mediated
Uptake of HBV and HDV Independently of Effects on Bile Acid
Transport"
- Publication Number: 928
- Date and Time: October 21, 2017 from 2:00
PM to 7:30 PM
- Session: Hepatitis B: New and Approved
Treatment
- Location: Washington Convention Center, Hall
D
About TXL™
Tenofovir exalidex (TXL™) is a highly potent prodrug of the
antiviral tenofovir. Tenofovir is the active component of
both Vemlidy (tenofovir alafenamide) and Viread® (tenofovir
disoproxil fumarate). TXL’s novel liver-targeting prodrug structure
results in decreased systemic circulating levels of tenofovir,
thereby reducing the potential for renal and bone side effects.
ContraVir has completed a Phase 2a trial of TXL™, in which
HBV-infected subjects were administered doses up to 100 mg for 28
days and is now optimizing drug formulation to further enhance drug
delivery. To date, TXL™ has achieved clinical proof of concept for
antiviral activity and displayed an excellent safety, tolerability,
and pharmacokinetic profile. Based on the agent’s best-in-class
potential, ContraVir believes TXL™ can become the cornerstone of a
curative combination therapy for hepatitis B.
About CRV431
CRV431 is a non-immunosuppressive analog of cyclosporine A (CsA)
whose primary biochemical action is inhibition of cyclophilin
isomerase activity, playing a key role in protein folding. Other
viruses such as HIV-1 and HCV, similarly use cyclophilin for their
replication. CRV431 shows potential in experimental models to
complement current hepatitis B treatments by reducing multiple
markers of infection including HBV DNA, HBsAg, HBx, HBeAg, and HBV
uptake by cells. Studies have also demonstrated that CRV431
possesses anti-fibrotic activity which may further curb progression
of liver disease in patients.
About ContraVir Pharmaceuticals
ContraVir is a biopharmaceutical company focused on the
development and commercialization of targeted antiviral therapies
with a specific focus on developing a potentially curative therapy
for hepatitis B virus (HBV). The Company is developing two novel
anti-HBV compounds with complementary mechanisms of action. TXL™
currently in Phase 2a, is designed to deliver high intrahepatic
concentrations of TFV, while minimizing off-target effects caused
by high levels of circulating TFV. CRV431, the other anti-HBV
compound, is a next-generation cyclophilin inhibitor with a unique
structure that increases its potency and selective index against
HBV. ContraVir is also developing Valnivudine™, an orally available
nucleoside analogue prodrug; Valnivudine™ is currently in Phase 3
for the treatment of herpes zoster. In addition to direct
antiviral activity, Phase 2 data suggest that Valnivudine™ has the
potential to reduce the incidence of debilitating
shingles-associated pain known as post-herpetic neuralgia
(PHN). For more information visit www.contravir.com.
For further information, please contact:
Sharen Pyatetskaya
Director of Investor Relations
sp@contravir.com; (732) 902-4028
Contravir Pharmaceuticals Inc (NASDAQ:CTRV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Contravir Pharmaceuticals Inc (NASDAQ:CTRV)
Historical Stock Chart
From Sep 2023 to Sep 2024